ArticleJCI insight2021
Combination of CT and telomerase+ circulating tumor cells improves diagnosis of small pulmonary nodules.
Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Value of circulating tumor cell assisting low-dose computed tomography in screening pulmonary nodules based on existing liquid biopsy techniques: a systematic review with meta-analysis and trial sequential analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- Combining Napsin A expression with circulating tumor cell counts for enhanced identification of pulmonary adenocarcinoma in ground-glass nodules.Translational cancer research · 2026Article
- Advances in isolation and detection technologies and immunotherapy applications of circulating tumor cells (Review).Oncology reports · 2026Review
- A radiomics nomogram integrated with radiological features for preoperative prediction of lung nodule invasiveness: comparison with Lung-RADS.Translational lung cancer research · 2026Article
- PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy.Journal for immunotherapy of cancer · 2026Article
- Predictive Factors and Nomogram for Malignant Pulmonary Nodules (≤ 1 cm).Canadian respiratory journal · 2026Article
- Peripheral TERT- positive leukocytes as a biomarker of the local and systemic immune failure in early-stage lung adenocarcinoma progression.Molecular biomedicine · 2025Article
- Risk-stratified classification of pulmonary nodule malignancy via a machine learning model integrating imaging and cell-free DNA: a model development and validation study (DECIPHER-NODL).The Lancet regional health. Western Pacific · 2025Article
- Biomarkers for the diagnosis of indeterminate pulmonary nodules: are we there yet?Journal of thoracic disease · 2025Review
- Postoperative continuous saline bladder irrigation reduces active urinary cancer cells: a prospective study in NMIBC.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Comparison of SPEED and OSDI questionnaires for dry eye symptom in Chinese college students: a cross-sectional study.BMC ophthalmology · 2025Article
- Minimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.Cancer metastasis reviews · 2025Review
- Integrated multiomics signatures to optimize the accurate diagnosis of lung cancer.Nature communications · 2025Article
- Development of a prediction model for pulmonary nodules using circulating tumor cells combined with the uAI platform.Frontiers in oncology · 2025Article
- Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer.Discover oncology · 2024Article
- Circulating tumor cells are associated with lung cancer subtypes: a large-scale retrospective study.Translational lung cancer research · 2024Article
- Dynamically monitoring minimal residual disease using circulating tumour cells to predict the recurrence of early-stage lung adenocarcinoma.Journal of hematology & oncology · 2024Article
- A clinically effective model based on cell-free DNA methylation and low-dose CT for risk stratification of pulmonary nodules.Cell reports. Medicine · 2024Article
- Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application.Molecular cancer · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDEarly diagnosis and treatment are key to the long-term survival of lung cancer patients. Although CT has significantly contributed to the early diagnosis of lung cancer, there are still consequences of excessive or delayed treatment. By improving the sensitivity and specificity of circulating tumor cell (CTC) detection, a solution was proposed for differentiating benign from malignant pulmonary nodules.METHODSIn this study, we used telomerase reverse transcriptase-based (TERT-based) CTC detection (TBCD) to distinguish benign from malignant pulmonary nodules < 2 cm and compared this method with the pathological diagnosis as the gold standard. FlowSight and FISH were used to confirm the CTCs detected by TBCD.RESULTSOur results suggest that CTCs based on TBCD can be used as independent biomarkers to distinguish benign from malignant nodules and are significantly superior to serum tumor markers. When the detection threshold was 1, the detection sensitivity and specificity of CTC diagnosis were 0.854 and 0.839, respectively. For pulmonary nodules ≤ 1 cm and 1-2 cm, the sensitivity and specificity of CTCs were both higher than 77%. Additionally, the diagnostic ability of CTC-assisted CT was compared by CT detection. The results show that CT combined with CTCs could significantly improve the differentiation ability of benign and malignant nodules in lung nodules < 2 cm and that the sensitivity and specificity could reach 0.899 and 0.839, respectively.CONCLUSIONTBCD can effectively diagnose pulmonary nodules and be used as an effective auxiliary diagnostic scheme for CT diagnosis.FUNDINGNational Key Research and Development Project grant nos. 2019YFC1315700 and 2017YFC1308702, CAMS Initiative for Innovative Medicine grant no. 2017-I2M-1-005, and National Natural Science Foundation of China grant no. 81472013.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.